Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

and this hormone binds to glucagon receptors in the liver. This binding stimulates breakdown of glycogen and the release of glucose into the circulation. Although glucose is the main mediator of ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established atherosclerotic disease, CKD, or both.

However, there are not yet any approved therapies that follow Opko’s modality of simultaneously activating the GLP-1 and glucagon receptors. Big Pharmas have tended to evaluate dual GLP-1 ...

In people with type 2 diabetes, both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) were statistically significantly associated with ...